Black Bird Biotech Inc (DGDM) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access DGDM Annual Balance Sheets →
Examining balance sheet movements between Black Bird Biotech Inc and Sep 30 2022 reveals how Sep 30 2023 adjusts its asset composition and liability profile.
Quarterly Report, GAAP in USD millions
ITEM
(Sep 30 2023)
(Jun 30 2023) (Mar 31 2023) (Dec 31 2022) (Sep 30 2022)
Assets
Cash & cash equivalent0.00
Cash & Short-term Investments0.00
Accounts receivable0.00
Inventories0.08
Other Current Assets0.01
Total Current Assets0.09
Equipment/Property/Plant Net0.00
Deferred Costs, Noncurrent AS0.00
Other Repossessed Assets0.01
Other Assets, Noncurrent0.00
Deposit Asset Purchase0.01
Total Assets0.10
Liabilities
Accrued Liabilities, Current0.07
Notes Payable, Current NO0.74
Other Liabilities, Current0.22
Total Current Liabilities1.02
Total Long-term Debt0.00
Other liabilities, Noncurrent0.00
Third Party Notes Payable Net Of Discount Related To Conversion Feature Of0.18
Total Liabilities1.02
Stockholders' Equity
Common Stock Value1.79
Additional Paid In Capital Common Stock2.17
Retained Earnings / Accumulated Deficit-4.88
Other Equity0.00
Common Stockholder's Equity-0.92
Preferred Stockholder's Equity0.00
Total Stockholder's Equity-0.92
Liabilities & Stockholder's Equity0.10
4 historic quarters locked

Sign in to unlock the full Black Bird Biotech Inc balance sheet history.

About Black Bird Biotech Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001477932-23-008686

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.